Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.
These trade-offs can cause headaches for even the most seasoned professionals, which is why we started StockStory - to help you find high-quality companies that can grow their earnings no matter what. Keeping that in mind, here are three large-cap stocks with attractive long-term potential.
Intuit (INTU)
Market Cap: $86.3 billion
Originally named after its founding product "Intuitive for the first-time user," Intuit (NASDAQ:INTU) provides financial management software and services including TurboTax, QuickBooks, Credit Karma, and Mailchimp to help consumers and small businesses manage their finances.
Why Are We Fans of INTU?
- Software platform has product-market fit given the rapid recovery of its customer acquisition costs
- Highly efficient business model is illustrated by its impressive 27.5% operating margin, and its operating leverage amplified its profits over the last year
- Impressive free cash flow profitability enables the company to fund new investments or reward investors with share buybacks/dividends
At $313.75 per share, Intuit trades at 4x forward price-to-sales. Is now the right time to buy? See for yourself in our in-depth research report, it’s free.
ResMed (RMD)
Market Cap: $30.08 billion
Founded in 1989 to address the then-underdiagnosed condition of sleep apnea, ResMed (NYSE:RMD) develops cloud-connected medical devices and software solutions that treat sleep apnea, COPD, and other respiratory disorders for home and clinical use.
Why Do We Like RMD?
- Average constant currency growth of 9.1% over the past two years demonstrates its ability to grow internationally despite currency fluctuations
- Incremental sales significantly boosted profitability as its annual earnings per share growth of 15.2% over the last five years outstripped its revenue performance
- Free cash flow margin grew by 21.4 percentage points over the last five years, giving the company more chips to play with
ResMed is trading at $208.61 per share, or 18x forward P/E. Is now a good time to buy? Find out in our full research report, it’s free.
Allstate (ALL)
Market Cap: $68.31 billion
Born from a Sears, Roebuck & Co. initiative during the Great Depression with its famous "You're in good hands" slogan, Allstate (NYSE:ALL) is one of America's largest personal property and casualty insurers, offering protection for autos, homes, and personal property.
Why Are We Positive on ALL?
- 9.6% annual revenue growth over the last five years surpassed the sector average as its policies resonated with customers
- Share repurchases over the last two years enabled its annual earnings per share growth of 139% to outpace its revenue gains
- Annual book value per share growth of 34.9% over the last two years was superb and indicates its capital strength increased during this cycle
Allstate’s stock price of $265.15 implies a valuation ratio of 2.1x forward P/B. Is now the time to initiate a position? See for yourself in our comprehensive research report, it’s free.
Stocks We Like Even More
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.